5 Earnings Reports Catching Investors’ Attention
In this article, we discuss the 5 earnings reports catching investors' attention.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,707,368 | $445,572 | +5% | 0.52% |
| 2. | Impax Asset Management Ian Simm | 860,672 | $224,610 | -17% | 0.92% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 793,290 | $207,025 | +260% | 0.39% |
| 4. | Avidity Partners Management David Witzke And Michael Gregory | 545,600 | $142,385 | +95% | 2.96% |
| 5. | ARK Investment Management Catherine D. Wood | 421,775 | $110,071 | -55% | 0.45% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $196.34 | 4,243 | Officer, Director | 73,754 | 2021-08-19 | Filing | |
| $195.14 | 5,757 | Officer, Director | 69,511 | 2021-08-19 | Filing | |
| $197.91 | 15,000 | Director | 41,210 | 2021-08-02 | Filing | |
| $218.79 | 3,905 | Director | 26,210 | 2020-11-10 | Filing | |
| $217.49 | 4,270 | Director | 22,305 | 2020-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $275.09 | 36 | Officer | 41,660 | 2022-05-04 | Filing | |
| $263.98 | 306 | Officer | 64,760 | 2022-05-02 | Filing | |
| $264.37 | 4 | Officer | 41,696 | 2022-05-02 | Filing | |
| $261.79 | 65 | Officer | 41,700 | 2022-05-02 | Filing | |
| $260.44 | 23 | Officer | 41,765 | 2022-05-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 3,139,337 | $819,272,778 | 0.35% | |
| 2. | 351,478 | $91,725,214 | 0.54% | |
| 3. | 68,410 | $17,852,958 | 3.32% | |
| 4. | 41,571 | $10,848,783 | 0.13% | |
| 5. | 23,916,254 | $6,241,425 | 0.16% |
News See All
5 Biotech Stocks to Buy According to Billionaire David E. Shaw
In this piece, we will take a look at five biotechnology stocks to buy according to billionaire David E. Shaw.
Is Vertex Pharmaceuticals (VRTX) A Smart Long-Term Investment Choice?
Tweedy, Browne Company LLC, an investment management firm, published its “International Value Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
10 Biotech Stocks Hedge Funds Are Talking About
In this article, we present the list of the 10 biotech stocks hedge funds are talking about.
Here’s a Great Reason to Invest in Vertex Pharmaceuticals (VRTX)
Harding Loevner, an investment management firm, published its “Global Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
10 Biotech Stocks to Sell Now According to Cathie Wood
In this article, we discuss 10 biotech stocks to sell now according to Cathie Wood.
Were Hedge Funds Illusioned With Vertex Pharmaceuticals Incorporated (VRTX)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
10 Stocks That Beat Quarterly Expectations
In this article, we will take a look at the 10 stocks that beat the quarterly expectations.
5 Healthcare Stocks to Buy According to Billionaire DE Shaw
In this article, we discuss the 5 healthcare stocks to buy according to billionaire D E Shaw.
Hedge Funds Are Souring On Vertex Pharmaceuticals Incorporated (VRTX)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
Billionaire Hedge Funds
